Skip to main content

Table 4 Treatment with obinutuzumab-chlorambucil based on age and CIRS score

From: Real world risk of infusion reactions and effectiveness of front-line obinutuzumab plus chlorambucil compared with other frontline treatments for chronic lymphocytic leukemia

Treatment characteristic

Total

Age at treatment

CIRS

75 + 

Under 75

P-value

8 + 

Under 8

P-value

Achieved full dose of chlorambucil

26 (38.81)

6 (20.69)

20 (52.63)

 < 0.01a

15 (40.54)

11 (36.67)

0.75a

Completed 6 cycles of obinutuzumab

46 (68.66)

18 (62.07)

28 (73.68)

0.31a

25 (67.57)

21 (70.00)

0.83a

Number of chlorambucil doses, median (range)

10 (1–12)

8 (1–12)

10.5 (1–12)

0.06b

10 (1–12)

9 (1–12)

0.78b

Number of obinutuzumab doses, median (range)

9 (1–9)

8 (1–9)

9 (4–9)

-

9 (2–9)

9 (1–9)

-

  1. a Chi-square P-value
  2. b Wilcoxon-Mann Whitney P-value